Key Highlights
- Reported Q2 Revenue growth of 38% falls to roughly 17% excluding a $246 million non-cash Opzelura accrual Reversal ; much of the guidance raise reflects the same item.
- Jakafi remains about half of reported revenue and roughly 57% of the underlying base, with composition-of-matter patents expiring in mid and late 2028.
- 2026 GAAP Earnings will be depressed by a ~$1.27 billion IPR&D charge for Vega Therapeutics in Q3, making forward P/E unrepresentative.
- Incyte reported second-quarter results on 28 July.
A quarter flattered by an accrual reversal
Incyte ( Nasdaq :INCY) reported second-quarter results on 28 July. Total revenues reached $1.67 billion, up 38% year over year, and management lifted full-year net product sales guidance to $5.13–$5.26 billion from $4.77–$4.94 billion. "Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic Business development," said chief executive Bill Meury.
The fine print tempers it. Of that revenue, $246 million was what the company describes as "a one-time, non-cash benefit associated with the reversal of previously established accrual balances " for Opzelura, its ruxolitinib cream. Headline Opzelura sales of $450 million, up 173%, become $204 million and up 24% once the item is removed. On the same basis, group revenues were roughly $1.42 billion, growth nearer 17% than 38%. Most of the guidance raise lands in the Opzelura line, now $1.05–$1.10 billion against $750–$790 million previously, so a chunk of the upgrade is that same accounting benefit rather than incremental prescriptions.
The price action, and what drove it
Shares closed at $118.87 on 27 July, jumped 9.30% to $129.93 on results day, then fell 2.18%, 3.23% and 2.82% in the three sessions that followed, ending July at $119.52, effectively where they started. Market Capitalization stands at $24.2 billion. The final leg down was not company-specific: the SPDR S&P Biotech ETF fell 2.94% on 31 July. The stock remains up roughly 54% over 52 weeks, well inside a $73.81–$132.60 range.
The number that governs the Equity story
Jakafi generated $817 million in the quarter, up 7%. That is 49% of reported revenue and about 57% of the underlying figure excluding the one-off. Add $124 million of Jakavi royalties from Novartis and more than half the business still rests on one molecule. Full-year Jakafi guidance was left unchanged at $3.22–$3.27 billion.
Incyte's 2025 Form 10-K states that composition-of-matter patents covering ruxolitinib and its salt, "including applicable extensions, currently expire in mid and late 2028." The filing lists 2028 as the estimated minimum market exclusivity date in the US, Europe and Japan. Seven per cent growth on a Franchise with 30 months of protection left is the central tension.
The defense is Jakafi XR. The FDA approved the once-daily extended-release formulation in May 2026 across myelofibrosis, polycythemia vera and chronic graft-versus-host disease, and Incyte now folds XR sales into the Jakafi guidance line. Converting prescribers before generic immediate-release ruxolitinib arrives is the strategy; the company has not disclosed conversion rates, and how much of the franchise survives 2028 is unproven.
Margins, cash and a $1.25 billion bet
Cost of product revenues was $105 million, just 7% of net sales. GAAP R&D was $517 million and SG&A $352 million, producing $698 million of GAAP Operating Income , $586 million of Net Income and diluted EPS of $2.81 ($3.09 non-GAAP). Across the first half, revenues were $2.95 billion, net income $888.9 million and Operating Cash Flow $877.0 million against $310.8 million a year earlier. Cash and marketable securities finished at $4.54 billion versus roughly $38 million of Debt .
That Balance Sheet funded the quarter's other news. Incyte closed the Acquisition of Vega Therapeutics on 6 July for $1.25 billion upfront plus up to $750 million in sales milestones, buying latarcibart (VGA039), an anti-Protein S antibody in Phase 3 for von Willebrand disease that could offer monthly subcutaneous prophylaxis where patients now receive intravenous infusions. The upfront will be expensed as acquired in-process R&D of about $1.27 billion in the third quarter, in both GAAP and non-GAAP results. That, plus $50 million of incremental latarcibart spending, is why combined R&D and SG&A guidance jumped to $4,915–$4,995 million from $3,495–$3,675 million. Investors should read 2026 earnings accordingly. Separately, the 10-Q shows no share repurchases in the first half; excise tax paid on Buybacks was zero, against $19.1 million a year earlier.
What is actually diversifying the base
The smaller brands are growing off low bases: Niktimvo $60 million (+67%), Monjuvi/Minjuvi $54 million (+72%), Zynyz $50 million (+460%), Iclusig $34 million (+5%), Pemazyre $23 million (+6%). Hematology and oncology guidance is $860–$890 million for the year.
Two near-term expansions matter most. Tafasitamab's Phase 3 frontMIND trial hit its primary endpoint in previously untreated DLBCL, cutting the risk of progression or death by 25% (HR 0.75, p=0.0194), with three-year PFS of 67.3% versus 60.7%; interim overall survival favored the combination but was not statistically significant (HR 0.85, p=0.2703). Regulatory submissions were accepted in the second quarter, with US approval and launch expected in the first quarter of 2027. Povorcitinib's NDA in moderate-to-severe hidradenitis suppurativa was accepted in the first quarter of 2026; Incyte anticipates EU approval and launch in late 2026 and US launch in the first quarter of 2027.
Further out sit INCA033989, a mutant-calreticulin antibody now in the registrational Phase 3 EXCALIBUR-ET2 study in essential thrombocythemia, and Opzelura's own Phase 3 TRuE-HS1/HS2 program in mild-to-moderate hidradenitis suppurativa, with topline data guided for the fourth quarter. Ten readouts, four from registrational trials, are expected in the second half.
The bull and bear cases, and the price
Bulls point to a company with a real cost structure, 7% cost of goods, 31.7% trailing operating Margin , $1.92 billion of trailing free cash flow, that is finally launching more than one drug at a time, with net cash even after Vega and no Dividend obligation. On trailing earnings the shares change hands at 15.2 times, and around 12.6 times free cash flow.
Bears note that Jakafi grew 7%, that the guidance raise leans on an accrual reversal, that management is spending $1.25 billion on a Phase 3 asset in a rare bleeding disorder, and that nothing in the portfolio yet approaches $3 billion of annual sales. The consensus is telling: of 26 to 27 analysts tracked by data aggregators, 14 rate the stock hold. Its overview page shows an average target of $122.96 while its forecast page shows $114.55, either way, close to or below the last close. Forward earnings multiples above 40 times reflect the Vega charge, not underlying Economics , and are not meaningful this year.
What to watch
Whether the pipeline breaks the Jakafi dependence is, on this evidence, still undecided, the non-Jakafi base is compounding fast but still amounts to under a third of underlying revenue, and 2028 is close. The next real tests are the fourth-quarter povorcitinib and Opzelura hidradenitis readouts and the EU launch, followed by two US launches in early 2027.
Upcoming Catalysts
- European Commission decision on Opzelura in moderate atopic dermatitis, expected Q3 2026. Follows a positive CHMP opinion in June and underpins the raised Opzelura guidance.
- Q3 2026 results, expected late October 2026. First quarter carrying the Vega IPR&D charge and early Jakafi XR conversion data.
- TRuE-HS1/HS2 Phase 3 topline for Opzelura in mild-to-moderate hidradenitis suppurativa, Q4 2026. Would extend the cream beyond atopic dermatitis and vitiligo.
- Povorcitinib EU approval and launch in moderate-to-severe HS, anticipated late 2026; US launch guided for Q1 2027.
- STOP-PN1/PN2 Phase 3 data for povorcitinib in prurigo nodularis, Q4 2026. Tests the breadth of the JAK1 inflammation franchise.
Principal Risks
- 2028 ruxolitinib exclusivity loss. More than half the underlying revenue base is exposed, and the Jakafi XR conversion strategy is unproven.
- Quality of reported growth. A $246 million non-cash reversal inflated Q2 revenue and the guidance raise; underlying Opzelura growth was 24%.
- Capital allocation. The $1.25 billion Vega upfront buys a single Phase 3 rare-disease asset; buybacks paused in the first half of 2026.
- Launch execution. Tafasitamab in frontline DLBCL and povorcitinib in HS both face crowded, competitive markets, and frontMIND's interim overall survival result was not statistically significant.
- Sector Beta . The 31 July decline tracked a 2.94% fall in the biotech ETF; the shares move with sentiment as well as fundamentals.
Conclusion
Reported Q2 revenue growth of 38% falls to roughly 17% excluding a $246 million non-cash Opzelura accrual reversal; much of the guidance raise reflects the same item. Set against that: More than half the underlying revenue base is exposed, and the Jakafi XR conversion strategy is unproven. The next real test: European Commission decision on Opzelura in moderate atopic dermatitis, expected Q3 2026.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...